1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Zimbabwe Pharmaceuticals and Healthcare Report Q4 2016

Zimbabwe Pharmaceuticals and Healthcare Report Q4 2016

  • October 2016
  • -
  • Business Monitor International
  • -
  • 70 pages

Includes 3 FREE quarterly updates

BMI View:

Zimbabwe is one of the top 20 fastest growing pharmaceutical markets in 2016; however growth will slow considerably in the coming years. Weak economic conditions and a drop in revenue from taxes will further impact the already severely underfunded public healthcare services. Furthermore, a high abundance of counterfeit drugs and increasing political tensions make Zimbabwe one of the least attractive markets in the region for multinational drugmakers.


Headline Expenditure Projections

- Pharmaceuticals: USD380mn in 2015 to USD400mn in 2016; +4.5% in US dollar terms. Forecast unchanged from last quarter. In BMI's Risk/Reward Index (RRI) for Q416, Zimbabwe scores a poor 25.0 out of 100, unchanged from last quarter. The country is ranked 30th out of the 32 markets surveyed in the Middle East and Africa (MEA) region, just above Angola (24.9). Despite its rapidly growing population (Population Growth score of 4.5 out of 5), Zimbabwe will remain one of the least-attractive pharmaceutical and healthcare markets regionally and globally, due to the elevated political, economic and social risks, as well as the lack of finances for adequate healthcare provision and capacity utilisation.

Table Of Contents

Zimbabwe Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Zimbabwe 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Zimbabwe 2012-2020) 13
Healthcare Market Forecast 14
Prescription Drug Market Forecast 16
Patented Drug Market Forecast 17
Generic Drug Market Forecast 18
Pharmaceutical Trade Forecast 19
Table: Pharmaceutical Trade Data And Forecasts (Zimbabwe 2014-2020) 21
Industry Risk/Reward Index 22
Middle East And Africa Risk/Reward Index - Q4 2016 22
Zimbabwe Risk/Reward Index 30
Rewards 30
Risks 30
Regulatory Review 32
Regulatory Regime 32
Intellectual Property Issues 34
Pricing And Reimbursement Regime 35
Market Overview 38
Healthcare Sector 39
Table: Zimbabwe: Healthcare Facilities 39
Research and Development 45
Clinical Trials 46
Epidemiology 47
Competitive Landscape 50
Research-Based Industry 50
Table: Multinational Market Activity 51
Generic Drugmakers 52
Pharmaceutical Distribution And Retail Sector 53
Company Profile 54
Datlabs 54
Varichem Laboratories 56
Zimbabwe Pharmaceuticals and Healthcare Report Q4 2016$$
Demographic Forecast 59
Table: Population Headline Indicators (Zimbabwe 1990-2025) 60
Table: Key Population Ratios (Zimbabwe 1990-2025) 60
Table: Urban/Rural Population and Life Expectancy (Zimbabwe 1990-2025) 61
Table: Population By Age Group (Zimbabwe 1990-2025) 61
Table: Population By Age Group % (Zimbabwe 1990-2025) 62
Glossary 64
Methodology 66
Pharmaceutical Expenditure Forecast Model 66
Healthcare Expenditure Forecast Model 66
Notes On Methodology 67
Risk/Reward Index Methodology 68
Index Overview 69
Table: Pharmaceutical Risk/Reward Index Indicators 69
Indicator Weightings 70

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.